ストックスクリーナーアプリを入手
111.90
2.37%
-2.72
アフターアワーズ：
111.95
0.05
+0.04%
前日終値:
$114.62
開ける：
$113.74
24時間の取引高:
7.00M
Relative Volume:
0.64
時価総額：
$276.38B
収益：
$64.93B
当期純損益:
$18.26B
株価収益率:
15.38
EPS:
7.2751
ネットキャッシュフロー:
$12.36B
1週間 パフォーマンス:
-6.02%
1か月 パフォーマンス:
-3.84%
6か月 パフォーマンス:
+27.90%
1年 パフォーマンス:
+40.16%
1日の値動き範囲:
$111.50
$114.03
1週間の範囲:
$111.50
$119.36
52週間の値動き範囲:
$73.31
$125.14
Merck Co Inc Stock (MRK) Company Profile
Compare MRK vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
111.90 | 276.38B | 64.93B | 18.26B | 12.36B | 7.2751 |
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-02-13 | アップグレード | Deutsche Bank | Hold → Buy |
| 2026-01-08 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-10-13 | 再開されました | Citigroup | Neutral |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-02-18 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-02-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-08 | ダウングレード | Truist | Buy → Hold |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
Merck & Co., Inc. $MRK is Munich Reinsurance Co Stock Corp in Munich's 4th Largest Position - MarketBeat
J.P. Marvel Investment Advisors LLC Has $3.02 Million Holdings in Merck & Co., Inc. $MRK - MarketBeat
Concurrent Investment Advisors LLC Grows Position in Merck & Co., Inc. $MRK - MarketBeat
Generali Investments Management Co LLC Raises Stock Position in Merck & Co., Inc. $MRK - MarketBeat
China Universal Asset Management Co. Ltd. Sells 19,894 Shares of Merck & Co., Inc. $MRK - MarketBeat
Jim Cramer Says “Merck Is Terrific” - Yahoo Finance
Is Merck & Co. (MRK) One of the Best Bear Market Stocks to Invest in Right Now? - Insider Monkey
Infinimmune and Merck (MRK) Enter into an Antibody Discovery Agreement - Insider Monkey
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, - PharmiWeb.com
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc. - BioSpace
Mental Health Clinical Trials Research Report 2026: $4.89 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
Merck & Co., Inc. $MRK Shares Purchased by Cadinha & Co. LLC - MarketBeat
Arizona State Retirement System Sells 31,306 Shares of Merck & Co., Inc. $MRK - MarketBeat
MRK Stock Quote Price and Forecast - CNN
Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Merck & Co., Inc. $MRK Shares Sold by Teacher Retirement System of Texas - MarketBeat
United Asset Strategies Inc. Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (MRK) Gains FDA Priority Review for KEYTRUDA Regimen in Muscle-Invasive Bladder Cancer - Insider Monkey
Merck & Co., Inc. $MRK Shares Bought by Caprock Group LLC - MarketBeat
B. Metzler seel. Sohn & Co. AG Increases Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (MRK) to Release Earnings on Thursday - MarketBeat
Merck & Co. Inc. (MRK) Poised to Drive R&D and Operational Efficiency via New Google Cloud Agentic AI PartnershipUpside Surprise - Xã Thanh Hà
Merck & Co (MRK) Proxy filing Summary - Quartr
Merck to partner with Google Cloud on AI initiatives - Reuters
Merck & Co., Inc. $MRK Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
KLP Kapitalforvaltning AS Cuts Position in Merck & Co., Inc. $MRK - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Has $4.84 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
PFG Advisors Sells 11,759 Shares of Merck & Co., Inc. $MRK - MarketBeat
CPC Advisors LLC Increases Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp - MarketBeat
MRK Stock Price, Quote & Chart | MERCK & CO. INC. (NYSE:MRK) - ChartMill
Merck & Co., Inc. (MRK)Phase 3 Oncology Trial Setback Triggers Near-Term Pullback, Long-Term Upside Remains IntactNet Debt/EBITDA - Cổng thông tin điện tử tỉnh Tây Ninh
A Look at Merck & Co Inc (MRK) After 3.9% Decline -- GF Value $1 - GuruFocus
Merck And Eisai’s Keytruda/Lenvima/Welireg Trial In Kidney Cancer Fails - Citeline News & Insights
US FDA approves Merck's pill combo to treat HIV infection - Reuters
Merck's new once-daily HIV pill hits pharmacies after FDA nod - Stock Titan
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) - Business Wire
Why Is Merck Stock Falling Tuesday? - Benzinga
FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC - BioWorld News
Merck & Co Inc Stock (MRK) Moved Down by 4.19% on Apr 21: A Full Analysis - TradingKey
Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock? - TradingView
Novem Group Purchases 9,205 Shares of Merck & Co., Inc. $MRK - MarketBeat
SageGuard Financial Group LLC Acquires Shares of 14,280 Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) - ACN Newswire
Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda - GlobeNewswire
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock new upside? - AD HOC NEWS
Duncker Streett & Co. Inc. Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - GlobeNewswire Inc.
Lobbying Update: $4,150,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock sustained up - AD HOC NEWS
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
1.36%
6.88%
大文字化:
|
ボリューム (24 時間):